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Abstract
Cilostazol is clinically used for the treatment of ischemic symptoms in patients with chronic peripheral arterial obstruction
and for the secondary prevention of brain infarction. Recently, it has been reported that cilostazol has preventive effects on
atherogenesis and decreased serum triglyceride in rodent models. There are, however, few reports on the evaluation of
cilostazol using atherosclerotic rabbits, which have similar lipid metabolism to humans, and are used for investigating the
lipid content in aorta and platelet aggregation under conditions of hyperlipidemia. Therefore, we evaluated the effect of
cilostazol on the atherosclerosis and platelet aggregation in rabbits fed a normal diet or a cholesterol-containing diet
supplemented with or without cilostazol. We evaluated the effects of cilostazol on the atherogenesis by measuring serum
and aortic lipid content, and the lesion area after a 10-week treatment and the effect on platelet aggregation after 1- and
10-week treatment. From the lipid analyses, cilostazol significantly reduced the total cholesterol, triglyceride and
phospholipids in serum, and moreover, the triglyceride content in the atherosclerotic aorta. Cilostazol significantly reduced
the intimal atherosclerotic area. Platelet aggregation was enhanced in cholesterol-fed rabbits. Cilostazol significantly
inhibited the platelet aggregation in rabbits fed both a normal diet and a high cholesterol diet. Cilostazol showed anti-
atherosclerotic and anti-platelet effects in cholesterol-fed rabbits possibly due to the improvement of lipid metabolism and
the attenuation of platelet activation. The results suggest that cilostazol is useful for prevention and treatment of
atherothrombotic diseases with the lipid abnormalities.
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Introduction
According to the response-to-injury hypothesis, endothelial
dysfunction triggers atherosclerosis progression [1]. Platelets are
activated and aggregated on the exposed subendothelial tissues
when the endothelium is wounded in the atherosclerotic lesion.
Atherosclerosis also progresses with an elevation of serum
cholesterol, and platelets have been shown to be activated in
patients and rabbits with hypercholesterolemia [2–3]. If the
hypercholesterolemia continues for a long period, atherosclerosis
progresses in major arteries, and eventually may result in
cardiovascular diseases. Since platelets play a pivotal role in
atherosclerosis progression, they represent a key target for anti-
atherothrombotic therapy [4].
For the evaluation of platelet function in atherothrombotic
diseases, platelet aggregation can be measured. However, the
conventional light transmission method [5] is not suitable for the
measurement of platelet aggregation under a hyperlipidemic
condition because the chylous plasma hampers light transmission.
As an alternative method, platelet aggregation can be measured
using whole blood with impedance or screen filtration pressure
(SFP) [6–7]. The SFP method has been demonstrated to be
reproducible in addition to being easy to handle [8].
Cilostazol, a selective inhibitor of phosphodiesterase 3, is
a vasodilating anti-platelet drug [9]. It has been used for the
treatment of ischemic symptoms in patients with chronic
peripheral arterial obstruction and for the secondary prevention
of brain infarction [9–10]. In experimental studies, cilostazol has
been shown to prevent thrombus formation indicating its potent
anti-thrombotic effect based on its inhibitory action towards
platelet function [11–12]. Recently, it has been reported that
cilostazol attenuated atherosclerosis in low density lipoprotein
receptor knock out mice and Apo-E knock out mice [13–15].
Some reports indicated that cilostazol improved lipid metabolism.
For example, cilostazol decreased serum triglyceride and increased
the serum high-density lipoprotein cholesterol (HDL-C) in mice
[13–15], rats [16–17] and human [18–22]. In the present study,
we analyzed for the first time, the serum lipoprotein from rabbits
treated with cilostazol using high-performance liquid chromatog-
raphy (HPLC).
Transgenic mice and rabbits have been extensively used as
atherosclerosis-prone experimental animals. However, mice and
rats are naturally deficient in cholesteryl ester transfer protein
activity, unlike humans and rabbits. It is known that New Zealand
White rabbits have low plasma total cholesterol concentrations,
high cholesteryl ester transfer protein activity, low hepatic lipase
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providing a unique system in which to assess the effects of human
transgenes on plasma lipoproteins and atherosclerosis susceptibility
[23–24]. Additionally, as the rabbits become hyperlipidemic by
eating a high fat diet, it makes them an appropriate model to assess
the effects of drugs for their potential use in the treatment of
dyslipidemia.
In the present study, we evaluated whether cilostazol prevents
atherogenesis and platelet aggregation in hypercholesterolemic
rabbits as they have more similar pathologic characteristics to
human atherosclerosis than mice.
Results
Atherosclerotic Area and Aortic Lipids
The rate of the atherosclerotic area in the whole aorta in the
control group was 44.4613.6% and it was significantly attenuated
by cilostazol treatment (28.8610.3%, p=0.0185) as shown in
Figure 1. The reduction in atherosclerotic areas by cilostazol
treatment was also significant in both the thoracic aorta (control :
cilostazol, 48.4612.2:35.8612.6%, p=0.0443) and the abdomi-
nal aorta (control : cilostazol, 38.2616.2:17.6612.6%,
p=0.0087). On the other hand, the triglyceride (TG) content in
the cilostazol group was significantly lower than in the control
group in the arch and the whole aorta (arch: 4.061.1 versus
2.060.4 mg/g, p=0.006, whole: 3.561.3 versus 1.560.4 mg/g,
p=0.029) as shown in Figure 2. The total cholesterol (TC)
contents in the cilostazol group tended to be lower than in the
control group in the arch and the whole artery (arch: 45.8614.2
versus 28.0611.0 mg/g, p=0.058, whole: 24.168.2 versus
14.465.7 mg/g, p=0.062). The free cholesterol (FC) and
phospholipid (PL) did not differ between the control and cilostazol
groups in each region. The wet weights of the aortas showed no
differences between the control group and cilostazol group.
Intimal Macrophages
The results of immunohistochemical staining of macrophages in
the proximal ascending aorta are shown in Figure 3. The mean
values of the macrophage-positive areas did not differ between the
control group (1.3260.71 mm
2) and the cilostazol group
(1.4661.33 mm
2). However, two of the five samples in the
cilostazol group did not have a macrophage-positive area,
although all samples in the control group had macrophages.
Additionally, the same section was stained by the Elastica-van
Gieson method. The ratio of intima/media thickness in the aorta
when measured at the same location did not differ between the
two groups (data not shown).
Platelet Aggregation
Platelet aggregability was expressed as a platelet aggregatory
threshold index (PATI) value which is the concentration of agonist
required to cause 50% platelet aggregation. Thus, if the PATI
value for a certain condition is high, it means that platelet
aggregability is suppressed under that condition. The PATI value
for the high cholesterol diet was significantly lower than that in
a normal diet indicating that platelet aggregability was enhanced
by high-cholesterol feeding (Figure 4-A). When rabbits were fed
a normal diet, cilostazol significantly inhibited the platelet
aggregation 1 week after drug treatment (Figure 4-B). Further-
more, cilostazol significantly prevented the platelet aggregation 1
week after drug treatment in rabbits fed a 0.5% cholesterol diet
(Figure 4-C). The inhibitory effect of cilostazol was maintained 10
weeks after drug treatment. A significant linear correlation was
observed between the serum TC concentrations and the PATI
values prior to drug treatment (Figure 4-D, correlation coefficient:
r=–0.6897, p,0.001).
Serum Lipids and Other Biomarkers
Changes in serum lipids and other biomarkers are shown in
Table 1. Serum TC, TG and PL levels were gradually elevated
until the 10th week in the control group fed the 0.5% cholesterol
diet. The elevation of the serum lipids was significantly reduced by
cilostazol treatment; TC: p=0.0435, TG: p=0.0105 and PL:
p=0.0144 (group*time interaction in repeated measures analysis of
variances). Serum FC also increased in the control group and
tended to be suppressed by cilostazol treatment (p=0.1169,
group*time). Serum HDL-C did not show any change in the
control but increased in the cilostazol group from the 2nd week to
the 4th week (p=0.0239, group*time, p=0.0361, group differ-
ence). Using serum glutamate oxaloacetate transaminase (GOT),
glutamate pyruvate transaminase (GPT) and alkaline phosphatase
(ALP) as indices of hepatic function no differences between the
control and cilostazol groups were noted. Serum C-reactive protein
(CRP), an index of inflammation, markedly increased until the 10th
week although the CRP levels contained considerable individual
variability. Cilostazol did not affect the elevation of serum CRP. By
serum TG monitoring by HPLC, the high fat diet increased TG in
very low-density lipoprotein and chylomicron fractions, and
cilostazol reduced TG in the same fractions (Figure 5).
Serum Concentration of Cilostazol
Each morning, blood samples were collected to measure the
cilostazol concentration in serum 1 hour after feeding. The serum
concentrations of cilostazol were 256686 ng/mL from rabbits fed
a normal diet and 2946198 ng/mL from rabbits fed a high-
Figure 1. Comparison of atherosclerotic areas in aorta. Plaques
areas in the aorta of a typical animal in each group are shown by black
areas (A). Individual values in the control group are shown by closed
triangles (previous study) and closed circles (present study) and those in
the cilostazol group by opened triangles (previous study) and opened
circles (present study) and the horizontal bars in each group represent
the mean and the vertical bars are the SD (B). Control [n=10], cilostazol
[n=10]. *: p,0.05, **: p,0.01 versus control by a two-way ANOVA.
doi:10.1371/journal.pone.0039374.g001
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obtained in the clinic.
Discussion
The present study is the first to evaluate the effects of cilostazol
on atherosclerosis and ex vivo platelet aggregation in hypercho-
lesterolemic rabbits. We showed that cilostazol significantly
reduced the atherosclerotic area and the serum TG and increased
the serum HDL-C in addition to reducing TC and PL in
hypercholesterolemic rabbits. Additionally, it is particularly worth
noting that cilostazol significantly reduced the aortic TG in the
rabbits although aortic lipids were not measured in the previous
studies of atherosclerotic mice [13–15]. Cilostazol strongly re-
duced serum triglycerides with a slight increase in HDL-
cholesterol after 2 and 4 weeks of treatment. The results agree
well with the results from patients with peripheral arterial disease
(PAD) [18–20]. Cilostazol may be more effective at reducing
serum TG than increasing the HDL-C. Others have also reported
that cilostazol reduced pro-atherogenic lipoproteins such as
remnants-like particles, which is a strong contributor to cardio-
vascular risk, in the plasma of patients with PAD and/or type 2
diabetes [18–22]. Hirano et al. has reported that TG deposits were
found in the cardiac arteries of a patient with cardiomyopathy
[25], and the reduction of aortic TG content has clinical
implication. Maeda et al. studied the effect of cilostazol on the
TG secretion from the liver using an inhibitor of lipoprotein lipase
in rats, and found that the rate of TG secretion was decreased by
cilostazol [17]. On the other hand, Tani et al. have demonstrated
that cilostazol increased lipoprotein lipase activity, resulting in
a decrease in serum TG levels in streptozotocin-induced diabetic
rats [16]. These cilostazol-induced actions might contribute to the
reduction of serum TG in hypercholesterolemic rabbits. It is also
known that pharmacological agents that increase intracellular
cyclic AMP levels can enhance HDL3-mediated, sterol efflux from
cholesterol-loaded human skin fibroblasts and bovine aortic
endothelial cells [26]. The mild elevation of HDL-C by cilostazol
treatment noted in this study might be due to the same mode of
action because cilostazol increases intracellular cyclic AMP levels
by inhibiting phosphodiesterase 3. It is well-known that a high
level of low-density lipoprotein cholesterol and a low level of HDL-
C are principal risk factors for coronary heart disease and stroke
[27–28]. Serum TG is also one of the principal risk factors for
arterial thrombotic diseases [29–30]. Decreasing serum and aortic
TG by cilostazol treatment may contribute to the prevention of the
atherothrombotic diseases.
In contrast to the significant reduction in triglyceride content in
the aorta, treatment with cilostazol did not show a statistically
significant effect on the atherosclerotic area. We have investigated
the anti-atherosclerotic effect of cilostazol by treatment in a dose-
dependent manner (0.1, 0.3 and 1.0% cilostazol diet) in
cholesterol-fed rabbits ahead of the present study, and we observed
that a 0.3% cilostazol diet tended to reduce the atherosclerotic
area. Therefore, in this study, we confirmed the reproducibility of
the anti-atherosclerotic effect of cilostazol and examined in more
Figure 2. Effects of cilostazol on the lipid contents in the atherosclerotic aorta. Amounts of triglyceride (A), total cholesterol (B), free
cholesterol (C) and phospholipid (D) in different regions of the aorta. Individual values of the control group are shown by closed columns and those
of the cilostazol group by opened columns. Data represent means 6 S.D. Control [n=5], cilostazol [n=5]. *: p,0.05, **: p,0.01 versus control by t-
test.
doi:10.1371/journal.pone.0039374.g002
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platelet aggregation. The anti-atherosclerotic efficacy of cilostazol
was analyzed using the combined results from the dual study. A
significant linear correlation was observed between serum TG and
aortic TG (correlation coefficient: r=0.5745) but no correlation
between serum CRP and aortic TG was noted. In addition, from
the result obtained for the serum TG monitoring by HPLC, it was
speculated that the reduction of triglyceride in both very low-
density lipoprotein and chylomicron by cilostazol might contribute
to the reduction of triglyceride accumulation in the aorta.
Clarification of the mechanism of TG reduction by cilostazol
requires further study. The evaluation of the atherosclerotic area is
meaningful to detect whether the plaque is abundant or not.
Actually, more plaques were observed on the thoracic aorta than
on the abdominal aorta and the plaques were abundant around
the arterial bifurcation. It is possible that irregular local shear stress
might be involved in the plaque formation at such areas. The local
shear stress is one of the important factors affecting platelet
functions. Cilostazol inhibited the shear stress-induced platelet
aggregation [31].
From the immunostaining analysis of the macrophages in the
proximal ascending aorta, there was no difference between the
macrophage-positive areas in the two groups. However, it may be
a notable result that 2 of the 5 samples in the cilostazol group were
not stained by the anti-macrophage antibody, while all samples
were stained in the control group. Cilostazol inhibited the
monocyte adhesion to endothelia activated by remnant lipoprotein
[32]. The results in this study might partially reflect the inhibitory
effect of cilostazol on the monocyte adhesion. However, further
study is warranted to elucidate the exact effect of cilostazol on
macrophage accumulation in atherosclerotic plaques.
It has recently been reported that cilostazol inhibited the uptake
of modified low-density lipoprotein cholesterol and foam cell
formation in mouse peritoneal macrophages by reduction in the
expression of scavenger receptors [33]. Moreover, cilostazol has
been shown to inhibit the proliferation of smooth muscle cells and
protect from endothelial injury [34–35]. Monocyte adhesions to
the endothelium and platelets are also prevented by cilostazol [36–
37]. Thus, the pleiotropic effects of cilostazol, such as its anti-
platelet, anti-atherosclerotic and anti-inflammatory actions may be
important for preventing the progression of atherosclerotic disease.
The light transmission method has been generally used for the
measurement of platelet aggregation. In this conventional method,
the change in light transmission following addition of an agonist is
traced as a parameter of platelet aggregation, where the light
transmission of the platelet-poor plasma is set at 100% and that of
the platelet-rich plasma as 0%. Therefore, the method is unsuitable
for measuring platelet aggregation when the plasma is clouded due
to hyperlipidemia. Thus, in the present study, we measured platelet
aggregation using a SFP aggregometer as it is not affected by the
turbidity of plasma. The method is also easy as the preparation of
platelets by centrifugation is unnecessary. Additionally, generally
results obtained using the SFP method correlate well to the results
obtained by the light transmission method [5].
During the development of atherosclerosis, the interaction
between platelets and the vascular wall is critical. When the
vascular walls are damaged, platelets adhere to the subendothelial
surface containing collagen fibers and aggregate [1,38]. Platelet
sensitivity is enhanced with hypercholesterolemia in rabbits and
human [2–3]. Son et al. reported that the platelet aggregation in
the hypercholesterolemic rabbit was induced by a low concentra-
tion of collagen [3]. In the present study, platelet aggregability in
hypercholesterolemic rabbits was also enhanced, and this hyper-
reactivity was maintained for up to 10 weeks when fed a 0.5%
cholesterol diet. The correlation between the serum TC concen-
tration and the PATI was significant; the higher the serum TC, the
lower the PATI. It is known that lowering of the serum TC
attenuates platelet aggregation as well as atheroma formation [39].
Cilostazol inhibits platelet aggregation by various agonists, in
particular, it strongly inhibits platelet aggregation induced by
collagen [11], one of the major components of the subendothe-
lium. The inhibitory effect of cilostazol on platelet aggregation was
maintained throughout the duration of this study. Thus, the anti-
atherosclerotic effect of cilostazol might partly result from its
sustained anti-platelet effect.
In summary, cilostazol improved lipid levels in serum and
atherosclerotic aorta and inhibited the platelet aggregation
detected using a SFP whole blood aggregometer in hypercholes-
terolemic rabbits. Cilostazol may be useful to prevent atheroscle-
rotic progression through its anti-platelet effect and help to
improve lipid abnormalities in hypercholesterolemic patients.
Materials and Methods
Experimental Animals
Seven-week-old male rabbits (New Zealand White) were
purchased from Kitayama Labes (Nagano, Japan). To minimize
the number of the animals used, the rabbits were washed out for 2
weeks between the first platelet aggregation study with a normal
cholesterol diet and the second aggregation study with 0.5%
cholesterol diet. Rabbits were fed each particular diet at 100 g/
Figure 3. Immunohistochemical staining of macrophages in the
proximal ascending aorta. Cross sections of the proximal ascending
aorta were stained by an anti-macrophage RAM11 antibody. The brown
part represents the macrophage-positive area. Typical images are
shown for the control and cilostazol groups. Two of the five samples in
the cilostazol group were not stained by the RAM11 antibody (the right
image of cilostazol), although all samples were stained in the control
group.
doi:10.1371/journal.pone.0039374.g003
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accordance with the Guidelines for Animal Care and Use of
Otsuka Pharmaceutical Co., Ltd. The ethics committee specifi-
cally approved this study.
Design of Experiments
We first evaluated the platelet aggregation in rabbits fed
a normal diet in the presence or absence of cilostazol, and then all
the rabbits were fed the normal diet for 2 weeks to wash out the
drug. Next, the platelet aggregation was evaluated in rabbits fed
a high cholesterol diet. Finally, we evaluated the atherosclerotic
area in aorta and the lipids in the serum and aorta. Using the
combined results from the dual study, the evaluation of the
atherosclerotic area was carried out.
Materials
The SFP whole blood aggregometer was from Mebanix Co.,
Ltd. (WBA analyzer, Yokohama, Japan). Cilostazol was synthe-
sized at Otsuka Pharmaceutical Co., Ltd. Collagen was purchased
from Nycomed Arzneimittel Gmbh. (Munchen, Germany) and
sodium citrate from Sysmex (Kobe, Japan).
Measurement of Platelet Aggregation by SFP
Aggregometer
Measurement of platelet aggregation with the SFP aggreg-
ometer was carried out according to the method previously
described [7]. Briefly, blood was collected from animals into plastic
syringes containing sodium citrate at a final concentration of
0.38%. Suspensions of collagen were prepared at 10 times the final
concentrations at 4uC. Four reaction tubes containing 200 mL
aliquots of whole blood with a stirring bar were placed in the
incubation chamber at 37uC. The reaction tubes were pre-
incubated for 1 min at 37uC, and then 22.2 mL each of four
concentrations of collagen were added. Five minutes thereafter,
the filter-unit syringe with a screen micro-sieve was used to suck
the blood samples. A pressure sensor was connected to the syringe.
A negative pressure of –130 mmHg was set as 100% and 0 mmHg
as 0%. The platelet aggregation of each reaction tube was
determined as the pressure rate (%). The concentration of agonist
causing a 50% change of pressure rate was calculated and
expressed as the platelet aggregatory threshold index (PATI).
Evaluation of Cilostazol on Platelet Aggregation
We firstly evaluated the platelet aggregation in rabbits fed
a normal diet. Platelet aggregation was measured in twenty rabbits
and the PATI (pre) before drug treatment was calculated for each
animal. The rabbits were then divided into two groups (control
group and cilostazol group) with eight animals per group, and four
animals were excluded because of an outlier PATI. The PATI
(post) was measured 1 week after drug treatment, then, all the
rabbits were fed the normal diet for 2 weeks to wash out the drug.
Next, the platelet aggregation was evaluated in rabbits fed a 0.5%
Figure 4. Platelet aggregation in rabbits. Comparison of platelet aggregation between normal and hypercholesterolemic rabbits (A). Effect of
cilostazol on platelet aggregation in normal rabbits (B) or hypercholesterolemic rabbits (C). The control group are shown by closed circles and the
cilostazol group by open circles. Correlation between serum TC and PATI values (D). Normal rabbits are shown by closed triangles and
hypercholesterolemic rabbits by open triangles. Data represent means 6 S.D. Normal rabbit study: control [n=8], cilostazol [n=8],
hypercholesterolemic rabbit study: control [n=5], cilostazol [n=5]. **: p,0.01 versus control by t-test. PATI: Platelet aggregatory threshold index,
TC: total cholesterol, R: correlative rate.
doi:10.1371/journal.pone.0039374.g004
Cilostazol Reduced Aortic Triglyceride in Rabbits
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39374cholesterol diet. The total cholesterol in serum was measured
before and after feeding the 0.5% cholesterol diet for a week. After
feeding the 0.5% cholesterol diet for 1 week, platelet aggregation
was determined as the PATI (pre) for the high cholesterol diet
before drug treatment. Ten rabbits were excluded since the serum
TC level was too high (.700 mg/dL) or too low (,300 mg/dL)
or because of the outlier PATI, and the remaining animals were
allocated into two groups (control group and cilostazol group) with
five animals per group. A 0.5% cholesterol diet and 0.5%
cholesterol plus 0.3% cilostazol diet were fed to the control group
and the cilostazol group, respectively for 10 weeks. The platelet
aggregation was measured and the PATI (post) 1 week and 10
weeks after drug treatment was calculated for the rabbits fed a high
cholesterol diet.
Measurement of Serum Lipids and other Biomarkers
For the rabbits fed the high cholesterol diet, the blood was
collected before and 2, 4, 6, 8 and 10 weeks after drug treatment,
and the serum was obtained by centrifuging it at 20006g for 10
minutes at room temperature. Total cholesterol, TG, FC, PL and
HDL-C were measured as serum lipids, and GOT, GPT and ALP
were measured as indices of hepatic functions and CRP was used
as an index of inflammation. Serum lipids excluding FC, and
GOT, GPT and ALP were measured by the multi-function
automatic analyzer system (BiOLis 24i, Tokyo Boeki Machinery
Ltd, Tokyo, Japan). Serum FC was measured using a multi-plate
reader (Soft MAX Pro, Spectra MAX 190, Molecular Devices,
CA, USA) using reagents for the BiOLis 24i. Serum CRP was
measured by an enzyme-linked immunosorbent assay kit (Shi-
bayagi, Gunma, Japan). Lipoproteins were analyzed by HPLC
from 10 week serum samples. Serum was fractionated by gel
chromatography using a column for lipoprotein analyses (TSKgel
LipopropakXL, Tosoh, Japan). After gel filtration, lipoprotein was
colored with TG reaction liquid in reaction coils, and the
absorbance at 600 nm was monitored, and the elution pattern
was recorded.
Measurement of Atherosclerotic Areas
The analysis of the atherosclerotic lesion was performed by
Daugherty’s method with a slight modification [40]. Following the
last platelet aggregation study, rabbits were anesthetized by an
injection of pentobarbital sodium (40 mg/mL at volume of 1 mL/
Table 1. Changes of serum lipids and biomarkers.
Group Pre 2W 4W 6W 8W 10W
TC Control 475644 11096133 14926148 17816143 21476491 23986379
Cilostazol 422653 9636269 11406449 12836627 14666579 16186705 *
TG Control 21683 7 613 60625 110663 523626 569655
Cilostazol 21632 6 611 47624 59641 445671 470668 *
FC Control 10569 236637 539672 359659 5206101 5966124
Cilostazol 98612 219640 4326168 2626135 3596182 3936172
HDLC Control 22643 1 663 2 683 4 642 8 643 0 66
Cilostazol 22653 8 674 0 673 4 653 1 642 5 67* , {
PL Control 183614 352628 442630 525648 630656 7646198
Cilostazol 181625 344671 4116136 4206166 4746180 5206213 *
GOT Control 23612 33633 31618 27683 0 694 5 643
Cilostazol 32630 32625 30614 26611 28611 2569
GPT Control 38613 45624 52626 40612 44685 6 631
Cilostazol 946100 75659 80651 66642 61630 72645
ALP Control 6546178 401696 4866137 412659 364678 374691
Cilostazol 6636303 3366155 4626177 3846127 3596129 4316171
CRP Control 9556346 784363115 416764111 13418615039 11164610216 937606186537
Cilostazol 166561119 965364829 609764856 17544619860 996567674 23683621739
Concentrations of serum lipids and biomarkers were measured before and 2, 4, 6, 8, 10 weeks after drug administration. Data represent means 6 S.D. Control [n=5],
cilostazol [n=5]. *: p,0.05 (group*time), {:p ,0.05 (group) versus control by repeated measures ANOVA. TC: total cholesterol, TG: triglyceride, FC: free cholesterol, HDL-
C: high density lipoprotein cholesterol, PL: phospholipid, GOT: glutamate oxaloacetate transaminase, GPT: glutamate pyruvate transaminase, ALP: alkaline phosphatase,
and CRP: C-reactive protein. TC, TG, FC, HDL, PL is shown at mg/dL, GOT, GPT, ALP at U/L and CRP at ng/mL.
doi:10.1371/journal.pone.0039374.t001
Figure 5. Serum TG analysis by HPLC. Lipoproteins in 10 week
treatment serum samples were analyzed by HPLC. The mean value of
the control group is shown by a red line and the cilostazol group by the
blue line and the normal diet group by the green line. Control [n=5],
cilostazol [n=5], normal diet [n=3].
doi:10.1371/journal.pone.0039374.g005
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plate and their body hair was shaved. The abdomen and chest
were opened, and then blood (60 mL) was collected from the
abdominal vein. The aorta was perfused with ice-cold saline. The
length of the aorta from the origin of the aortic arch to a femoral
artery bifurcation was measured, and the aorta was excised and
placed in cold saline. The aorta was cut into two regions at the
diaphragm, i.e. the thoracic aorta including the arch and the
abdominal aorta, and was trimmed to remove extraneous tissues
under the stereomicroscope (SMZ800, Nikon, Tokyo, Japan), then
longitudinally incised, and the intimal sides were exposed. The
aortas were pinned on black rubber plates and photographed with
a digital camera (D80, Nikon, Tokyo, Japan). The whole intimal
and atherosclerotic areas were analyzed using image analyzers
(Photoshop, Adobe Systems, Tokyo, Japan and WinROOF,
Mitani Corporation, Tokyo, Japan). The ratio of the atheroscle-
rotic area to the whole intimal area was calculated. Plaque areas of
unstained aortas were measured in the present study because the
plaque areas strongly correlated with the Sudan IV staining areas
in the preliminary study (correlation coefficient: r=0.9898).
Measurement of Aortic Lipids
After obtaining the photograph, the thoracic aorta was further
separated into the arch and the residual thoracic aorta. The wet
weights of the aortas (arch, thoracic aorta, and abdominal aorta)
were weighed by an electronic balance (CP225D, Sartorius,
Tokyo, Japan). The aortas were chopped into fine pieces. The
extraction liquid (chloroform/methanol (2:1, v/v)) was added to
the chopped arteries, and they were homogenized by a digital
homogenizer (As-one, Osaka, Japan). The homogenates were
centrifuged at 8006g for 10 minutes. The upper-layer solution was
transferred into another tube and mixed with 0.36 M CaCl2/50%
methanol. The mixture was centrifuged at 8006g for 10 minutes,
and this washing procedure was repeated twice. The 100 mL
aliquot of the solution used to extract lipids was dried with 50%
Triton X-100 in chloroform on a dry-block bath (As-one, Osaka,
Japan). Isopropanol was added to the dried sample. Lipids (TC,
TG, FC and PL) in the samples were measured as serum lipids.
Histochemical Staining of the Aortic Cross Section
Proximal ascending aortas were fixed with 10% neutral buffered
formalin, embedded in paraffin, sectioned at 3 mm and adhered to
APS coated slides. Sections were stained with an automatic
immunohistochemical staining system (Venatana HX system
Discovery, Roche-Diagnostics) using a mouse monoclonal anti-
body against rabbit macrophage, RAM11 (1:200, Dako). Addi-
tionally, the same section was stained by the Elastica-van Gieson
method.
Statistical Analysis
For the PATI values, lipids in the aorta and the rate of RAM11
positive cells, the differences between the control group and the
cilostazol group were statistically analyzed by a t-test. For serum
lipids, the differences between two groups were statistically
analyzed by repeated measures analysis of variance (ANOVA).
The rate of the atherosclerotic area was statistically analyzed by
using two-way ANOVA. Factors included in the ANOVA model
were group and time interaction. The correlations between the
serum TC concentrations and PATI values, the serum TC and
serum TG, the plaque areas and the Sudan IV staining areas were
evaluated using Pearson’s correlation coefficient and correlation
coefficient test. Values were expressed as means 6 S.D. A p-value
,0.05 was considered significant. Analyses were performed using
the SAS software (release 9.1, SAS Institute Japan, Tokyo, Japan).
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